"Accelerating drug development with synthetic biology and next-generation sequencing."

A-Alpha Bio Inc. is a team of synthetic biologists and next-generation sequencing experts focused on disrupting the way that pharmaceutical companies discover, optimize, and characterize drugs. Central to its vision is AlphaSeq, the leading technology for quantitative, multi-target characterization of biologics and small molecules that modulate protein interactions.

​

A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology.